gmp
gmp

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fursultiamine

            Therapeutic Area: Ophthalmology Product Name: Alinamin

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Blackstone Life Sciences

            Deal Size: $2,277.2 million Upfront Cash: Undisclosed

            Deal Type: Divestment August 24, 2020

            Details:

            The portfolio to be divested includes a variety of over-the-counter medicines and health products. TCHC’s strong regional brands include Alinamin, and Benza.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Oxymetazoline

            Therapeutic Area: Ophthalmology Product Name: Upneeq

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: RVL Pharmaceuticals

            Deal Size: $89.0 million Upfront Cash: $25.0 million

            Deal Type: Licensing Agreement July 28, 2020

            Details:

            Under the agreement Santen will be responsible for further development of RVL-1201 and regulatory approvals as well as commercialization in its licensed territories under the agreement.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Brimonidine Tartrate,Brinzolamide

            Therapeutic Area: Ophthalmology Product Name: Ailamide

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 16, 2020

            Details:

            New combination ophthalmic solution for the treatment of glaucoma and ocular hypertension, AILAMIDE® Combination Ophthalmic Suspension has been launched in Japan on June 16, 2020.